- CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which can treat 155,000 newly diagnosed advanced primary head and neck cancer patients per year globally.
- Five-year survival: control arm 48.6%, Multikine arm 62.7% (N=380, p=0.0236, HR=0.68); in other words, 21,000 more patients would be alive after five years versus the current standard of care.
- Multikine had no safety issues, unlike any other cancer treatment.
- Multikine is the first treatment in 30 years for newly-diagnosed squamous cell head and neck tumors. As such, it serves an unmet medical need, which is important to FDA.
- FDA approval and multi-billion dollar commercial success is highly probable. The current market cap of ~$0.40 billion is unjustifiably low.
For further details see:
CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors